These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30073497)

  • 1. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers.
    Stewart M; Shaffer S; Murphy B; Loftus J; Alvir J; Cicchetti M; Lenderking WR
    Neurol Ther; 2018 Dec; 7(2):349-364. PubMed ID: 30073497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups.
    Rintell D; Heath D; Braga Mendendez F; Cross E; Cross T; Knobel V; Gagnon B; Turtle C; Cohen A; Kalmykov E; Fox J
    Orphanet J Rare Dis; 2021 Feb; 16(1):70. PubMed ID: 33557882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.
    Aimo A; Rapezzi C; Perfetto F; Cappelli F; Palladini G; Obici L; Merlini G; Di Bella G; Serenelli M; Zampieri M; Milani P; Licordari R; Teresi L; Ribarich N; Castiglione V; Quattrone F; De Rosis S; Vergaro G; Panichella G; Emdin M; Passino C
    Eur J Clin Invest; 2021 Nov; 51(11):e13598. PubMed ID: 33982288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study.
    Ponti L; Hsu K; Damy T; Villacorta E; Verheyen N; Keohane D; Wang R; Ines M; Kumar N; Munteanu C; Cappelli F
    Front Cardiovasc Med; 2023; 10():1238843. PubMed ID: 37711563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
    González-Moreno J; Losada-López I; Cisneros-Barroso E; Garcia-Pavia P; González-Costello J; Muñoz-Beamud F; Campistol JM; Fernandez-Torron R; Chapman D; Amass L
    Neurol Ther; 2021 Dec; 10(2):833-845. PubMed ID: 34331265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.
    Streicher N; Amass L; Wang R; Stephens JM; LeMasters T; Raina R; Merrill E; Sheikh FH
    Cardiol Ther; 2024 Jun; 13(2):359-368. PubMed ID: 38521883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caregiver's psychological well-being and quality of relationship with cardiac amyloidosis patients.
    Ponti L; Cappelli F; Perfetto F; Maver P; Smorti M
    Psychol Health Med; 2024; 29(1):66-78. PubMed ID: 38156665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.
    Ioannou A; Fontana M; Gillmore JD
    Heart Int; 2023; 17(1):27-35. PubMed ID: 37456349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes on familial amyloid polyneuropathy (FAP).
    Bolte FJ; Langenstroer C; Friebel F; Hüsing-Kabar A; Dugas M; Schmidt HH
    Orphanet J Rare Dis; 2020 Oct; 15(1):287. PubMed ID: 33054844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
    González-Moreno J; Dispenzieri A; Grogan M; Coelho T; Tournev I; Waddington-Cruz M; Wixner J; Diemberger I; Garcia-Pavia P; Chapman D; Gupta P; Glass O; Amass L;
    Cardiol Ther; 2024 Mar; 13(1):117-135. PubMed ID: 38117424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey exploring caregiver burden and health-related quality of life in hereditary transthyretin amyloidosis.
    Acaster S; Lo SH; Nestler-Parr S
    Orphanet J Rare Dis; 2023 Jan; 18(1):17. PubMed ID: 36698133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
    Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
    Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
    Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
    Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
    Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
    Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.
    Ikram A; Donnelly JP; Sperry BW; Samaras C; Valent J; Hanna M
    Amyloid; 2018 Sep; 25(3):197-202. PubMed ID: 30388377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
    Pilebro B; Suhr OB; Näslund U; Westermark P; Lindqvist P; Sundström T
    Ups J Med Sci; 2016; 121(1):17-24. PubMed ID: 26849806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.